{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:01:53Z","timestamp":1774119713392,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.clinthera.2011.11.009","type":"journal-article","created":{"date-parts":[[2011,12,14]],"date-time":"2011-12-14T03:47:58Z","timestamp":1323834478000},"page":"1974-1984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Tolerability of Indacaterol 75 \u03bcg Once Daily in Patients Aged \u226540 Years With Chronic Obstructive Pulmonary Disease: Results From 2 Double-Blind, Placebo-Controlled 12-Week Studies"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct01068600","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01072448","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Edward M.","family":"Kerwin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark H.","family":"Gotfried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl","family":"Lassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.11.009_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2466-10-11","article-title":"Efficacy and safety of indacaterol 150 \u03bcg once-daily in COPD: a double-blind, randomised, 12-week study","volume":"10","author":"Feldman","year":"2010","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.clinthera.2011.11.009_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","article-title":"Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium","volume":"182","author":"Donohue","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2011.11.009_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1183\/09031936.00045810","article-title":"Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison","volume":"37","author":"Kornmann","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2011.11.009_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thx.2009.125435","article-title":"Efficacy of a new once-daily long-acting inhaled \u03b22-agonist indacaterol versus twice-daily formoterol in COPD","volume":"65","author":"Dahl","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.clinthera.2011.11.009_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1378\/chest.10-1830","article-title":"Long-term safety and efficacy of indacaterol, a novel long-acting \u03b22-agonist, in subjects with COPD: a randomized, placebo-controlled study","volume":"140","author":"Chapman","year":"2011","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2011.11.009_bib8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2011.11.009_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2011.11.009_bib10","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self complete measure for chronic airflow limitation: the St. George's Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.clinthera.2011.11.009_bib11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George's Respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.clinthera.2011.11.009_bib12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnea","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2011.11.009_bib13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/COPD-200050666","article-title":"The MCID of the transition dyspnea index is a total score of one unit","volume":"2","author":"Mahler","year":"2005","journal-title":"COPD"},{"key":"10.1016\/j.clinthera.2011.11.009_bib14","series-title":"Applied Mixed Models in Medicine","author":"Brown","year":"1999"},{"key":"10.1016\/j.clinthera.2011.11.009_bib15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1183\/09031936.00123709","article-title":"Development and validation of the Capacity of Daily Living During the Morning Questionnaire and the Global Chest Symptoms Questionnaire in COPD","volume":"36","author":"Partridge","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2011.11.009_bib16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1183\/09031936.00051110","article-title":"Symptom variability in patients with severe COPD: pan-European cross-sectional study","volume":"37","author":"Kessler","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2011.11.009_bib17","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1183\/09031936.06.00145104","article-title":"Outcomes and markers in the assessment of chronic obstructive pulmonary disease","volume":"27","author":"Jones","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1016\/j.clinthera.2011.11.009_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1164\/rccm.200206-583OC","article-title":"Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status","volume":"167","author":"Oga","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2011.11.009_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11136-005-3215-y","article-title":"Exacerbations, hospital admissions and impaired health status in chronic obstructive pulmonary disease","volume":"15","author":"Miravitlles","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2011.11.009_bib20","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.rmed.2008.05.007","article-title":"Identifying COPD patients at increased risk of mortality: predictive value of clinical study baseline data","volume":"102","author":"Halpin","year":"2008","journal-title":"Respir Med"},{"key":"10.1016\/j.clinthera.2011.11.009_bib21","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1164\/ajrccm.155.4.9105068","article-title":"Quality of life changes in COPD patients treated with salmeterol","volume":"155","author":"Jones","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2011.11.009_bib22","first-page":"181","article-title":"Monitoring and outcomes","volume":"16","author":"Jones","year":"2007"},{"key":"10.1016\/j.clinthera.2011.11.009_bib23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.rmed.2010.11.027","article-title":"Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD","volume":"105","author":"Worth","year":"2011","journal-title":"Respir Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811007260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811007260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:04Z","timestamp":1758962944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811007260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0149291811007260"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.11.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Tolerability of Indacaterol 75 \u03bcg Once Daily in Patients Aged \u226540 Years With Chronic Obstructive Pulmonary Disease: Results From 2 Double-Blind, Placebo-Controlled 12-Week Studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}